Artificial Intelligence and Venous Thromboembolism: a narrative review of applications, benefits, and limitations [0.03%]
人工智能与静脉血栓栓塞症：应用、优势及局限性的叙事性综述
Aya Mudrik,Orly Efros
Aya Mudrik
Background: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a leading cause of cardiovascular morbidity and mortality. Artificial Intelligence (AI) holds promise for...
Prevalence of Pre-Treatment Sarcopenia in Patients newly diagnosed with Lymphoma [0.03%]
新诊断淋巴瘤患者的前期肌少症患病率研究
Charlotte Nørregaard Grønset,Mary Jarden,Jan Christensen et al.
Charlotte Nørregaard Grønset et al.
Introduction Sarcopenia, defined by reduced muscle strength, mass, and performance, presents a significant challenge in cancer care due to its impact on treatment outcomes, quality of life, and survival. This study aimed to assess its preva...
Acute Promyelocytic Leukemia Presenting with Cranial Nerve Involvement and Clivus Mass [0.03%]
伴发颅神经受累和斜坡肿块的急性早幼粒细胞白血病
Ananya Chandrika Nanduri,Farah Ashraf,Swe Swe Hlaing et al.
Ananya Chandrika Nanduri et al.
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that has become highly curable with advances in targeted therapy. However, central nervous system (CNS) involvement is exceedingly rare in APL and poses sign...
Case Reports
Acta haematologica. 2025 Mar 29:1-15. DOI:10.1159/000545444 2025
Acquired FX Deficiency in Multiple Myeloma Without Concomitant Amyloidosis- A Rare Case Report [0.03%]
多发性骨髓瘤中罕见的获得性凝血因子缺乏病例报告（无并发淀粉样变性）
Roi Gat,Svetlana Trestman,Ilya Kirgner
Roi Gat
This case report presents a rare occurrence of acquired Factor X (FX) deficiency in a patient with Multiple myeloma (MM) without concomitant amyloidosis. The patient, a 64-year-old male with prior diagnosis of Smoldering MM, presented with ...
Case Reports
Acta haematologica. 2025 Mar 29:1-8. DOI:10.1159/000545479 2025
Mind-Body Intervention in Chronic Lymphocytic Leukemia During the Watch-and-Wait Phase: Benefits Linked to Intervention Duration [0.03%]
慢性淋巴细胞白血病观察等待阶段的心身干预：与干预时长相关的益处
Shirley Shapira,Barak Mizrahi,Naama Hirschberger et al.
Shirley Shapira et al.
Introduction: Mind-Body Interventions (MBI) are therapeutic practices that target the interactions between cognitive, emotional, and physiological systems to influence health outcomes. Previously, we demonstrated that MBI...
A Bibliometric Analysis of Immunotherapy in Diffuse large B-cell lymphoma from 2004 to 2024 [0.03%]
从2004年到2024年的弥漫大B细胞淋巴瘤免疫治疗的文献计量分析
Yanling Wu,Xiaomin Chen,Yang Liu et al.
Yanling Wu et al.
Introduction: Immunotherapy in DLBCL (diffuse large B-cell lymphoma disease) has become an active research area with great value and potential. However, bibliometric research in this area is still sparse. Through bibliome...
The Effect of T-Lymphocyte Subgroups at Diagnosis on The Prognosis of Chronic Lymphocytic Leukemia [0.03%]
诊断时T淋巴细胞亚群对慢性淋巴细胞性白血病预后的影响
Deniz Seyithanoglu,Esra Nazligul Sert,Murat Ozbalak et al.
Deniz Seyithanoglu et al.
Introduction: Changes in the number and functional capacity of T-lymphocytes have been reported in chronic lymphocytic leukemia (CLL) patients. The aim of this study was to examine the prognostic significance of T-lymphoc...
Hematological evaluation and management of menorrhagia in adolescents: Lessons from adolescent heavy menstrual bleeding clinics [0.03%]
青少年月经过多的血液学评估和管理：来自青少年月经过多多学科诊所的经验
Marganit Benish,Adi Shitrit Yarhi,Ivan Budnik et al.
Marganit Benish et al.
Introduction: Heavy menstrual bleeding (HMB) poses a significant concern among adolescents and can arise from bleeding disorders. This study aimed to compare the clinical presentations and treatment of adolescents with HM...
The Need for Concurrent Chemoimmunotherapy in Pediatric B-Cell Lymphoblastic Leukemia [0.03%]
儿童B细胞淋巴母细胞白血病中联合化疗和免疫治疗的必要性
David McCall,Seth E Karol,Nicholas J Short
David McCall
Editorial
Acta haematologica. 2025 Mar 7:1-7. DOI:10.1159/000545028 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon alfa-2b-njft in Polycythemia Vera [0.03%]
ECLIPSE-PV：一项随机、多中心研究，评估罗培干扰素阿尔法-2b-njft两种给药方案在真性红细胞增多症中的疗效、安全性和耐受性
John Mascarenhas,Prithviraj Bose,Christopher Hillis et al.
John Mascarenhas et al.
Ropeginterferon alfa-2b-njft (ropeg) was approved and recommended as a preferred cytoreductive treatment for polycythemia vera (PV). The approved regimen requires an initial dose of 100 μg or 50 μg if transitioning from hydroxyurea (HU) a...